Sutro Biopharma
STRO
80 hedge funds and large institutions have $189M invested in Sutro Biopharma in 2020 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 35 increasing their positions, 12 reducing their positions, and 2 closing their positions.
1,050% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 2
192% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 12
55% more capital invested
Capital invested by funds: $122M → $189M (+$67.5M)
33% more funds holding
Funds holding: 60 → 80 (+20)
1.63% more ownership
Funds ownership: 5.16% → 6.79% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$18.4M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$18.2M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$17.5M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$14.4M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$7.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.67M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$2.15M |
| 3 |
O
OrbiMed
New York
|
-$1.07M |
| 4 |
VM
VV Manager
Boston,
Massachusetts
|
-$952K |
| 5 |
JP Morgan Chase
New York
|
-$186K |
STRO Hedge Fund Activity: Q2 2020 in Review
80 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q2 2020, worth a combined $189M — up 55% from $122M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new STRO positions and 2 closed out — a net gain of 21 holders — while 35 added to existing stakes and 12 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $18.4M. The largest seller was Citadel Advisors, cutting an estimated $2.67M.
- 80 institutional investors held Sutro Biopharma (STRO) as of Q2 2020, up from 60 in Q1 2020.
- Funds reported $189M of Sutro Biopharma stock for Q2 2020, up 55% quarter-over-quarter.
- 23 funds opened new Sutro Biopharma positions in Q2 2020 and 2 closed out, a net change of +21 holders.
- The largest Sutro Biopharma buyer in Q2 2020 was RA Capital Management, an estimated $18.4M added.
- The largest Sutro Biopharma seller in Q2 2020 was Citadel Advisors, an estimated $2.67M sold.
Based on aggregated 13F filings for Q2 2020.